Media Details

  • Home
  • Media
  • Details
  2020-08-07 16:02:34

HWGB Biotech engages principal lawyer of Foster Garvey PC to explore business opportunities in US healthcare industry

KUALA LUMPUR, June 30, 2020 - HWGB Biotech Sdn Bhd is pleased to announce that the company has engaged Jeffrey Qiong Li, the principal lawyer of Foster Garvey PC to help exploring business opportunities in the US healthcare industry.  
HWGB Biotech Sdn Bhd, formerly known as HWG Consortium Sdn Bhd, is a wholly-owned subsidiary of main-board listed company Ho Wah Genting Berhad (HWGB, 9601). The group has recently proposed diversification of its existing businesses to include the healthcare-related industry such as the dietary supplement, biotechnology and healthcare technology sub-segments.
Foster Garvey is one of the largest legal firms based in the Pacific Northwest. With attorneys located in six cities across the United States and in Beijing, Foster Garvey Business attorneys help companies navigate an increasingly complex operating environment and work with them to understand their business goals and priorities in order to find the right solutions for their organizations.
By leveraging Mr. Jeffrey Qiong Li’s extensive business network in both US and China, HWGB Biotech Sdn Bhd hopes that it is able to tap or venture into the healthcare industry worldwide, especially to the US market.
Foster Garvey’s extensive experience allow them to capably serve the needs of companies in highly regulated industries such as transportation, banking and financial services, health care and telecommunications.
HWGB BioTech aims to provide a comprehensive range of big health products and solutions that adopts a preventive measure readily available to improve the livelihood of Malaysians.
Foster Garvey PC was established through the combination of Foster Pepper PLLC and Garvey Schubert Barer, PC, in 2019. Foster Garvey is one of the largest firms based in the Pacific Northwest with six offices in Seattle, Portland, Washington, D.C., New York, Spokane and Beijing. The firm provides clients, including several of the most influential and innovative companies, governments and individuals in the country, with an extended national and international reach across the full spectrum of legal services.
Jeffrey has extensive experience assisting companies in their capital-raising activities, including public offerings of equity and debt securities, private placements and registered direct offerings.
Jeffrey is the Co-Chair of the firm’s China Practice, and represents China companies on their outbound investments and mergers and acquisitions in the United States. He has advised Chinese strategic buyers (operating companies) and private equity funds in their acquisitions of chemical, pharmaceutical and machinery companies in the United States. Jeffrey has advised Chinese companies on corporate laws, including formation of new companies and establishment of joint ventures in the United States. In addition, he has advised U.S. companies on Chinese corporate and foreign investment laws, such as stock acquisition of Chinese companies, and has assisted in patent litigation and licensing in China. 
Media contact: